Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial.
Latest Information Update: 30 Jun 2021
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms PaDOMi
- 01 Jan 2021 Status changed from recruiting to completed.
- 07 Jan 2020 Last check against ClinicalTrials.gov: US National Institutes of Health
- 07 Jan 2020 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified January 2018).